A top ERA abstract presents a biomarker-based model that non-invasively estimates kidney fibrosis in patients with IgA ...

Atacicept, an investigational BAFF (B-cell activating factor)/APRIL (a proliferation-inducing ligand) dual inhibitor, significantly reduced proteinuria in patients with immunoglobulin A nephropathy ...

Phase 3 results revealed Monday led shares to surge and should yield an approval application in IgA nephropathy, a ...

Panelists discuss how step-therapy for immunoglobulin A (IgA) nephropathy is evolving toward a more personalized approach, ...

Panelists discuss how patient-reported outcomes including symptom burden, treatment-related adverse effects, preserved ...

An experimental medicine from Vera Therapeutics significantly reduced levels of toxic protein in the urine of patients with ...

FILSPARI holds strong market potential as the first FDA-approved non-immunosuppressive therapy for IgA nephropathy, a rare kidney disease with significant unmet needs. As more patients and providers ...

Biogen plans to initiate phase 3 trials of felzartamab in IgA nephropathy and primary membranous nephropathy in 2025. Felzartamab was originally developed by MorphoSys AG (now MorphoSys GmbH, a ...

The drug was originally developed by MorphoSys, which Novartis also acquired last year. Beyond AMR, Biogen is planning to initiate phase 3 trials of felzartamab in two kidney diseases, IgA nephropathy ...

Biogen plans to initiate Phase 3 trials of felzartamab in IgA nephropathy and primary membranous nephropathy in 2025. Felzartamab was originally developed by MorphoSys AG (now MorphoSys GmbH, a ...